LSC
URGN icon

Lyon Street Capital’s UroGen Pharma URGN Stock Holding History

Lyon Street Capital’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-32,841
Closed -$1.63M – 58
2018
Q1 		$1.63M Sell
32,841
-23,776
-42% -$1.19M 0.53% 45
2017
Q4 		$2.11M Buy
56,617
+14,876
+36% +$530K 0.7% 43
2017
Q3 		$1.32M Buy
+41,741
New +$921K 0.51% 52

Other funds holding URGN

MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return
HCM
Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Lyon Street Capital's URGN Position: Q2 2018 in Review

Lyon Street Capital sold out of UroGen Pharma (URGN) in Q2 2018, closing a stake of 32,841 shares — an estimated $1.63M sold.

Lyon Street Capital first reported a position in URGN in Q3 2017 and held it in 3 quarters. The position peaked at $2.11M in Q4 2017. 60 funds tracked by Wall St. Rank hold URGN as of Q2 2018.

  • Lyon Street Capital reported no remaining UroGen Pharma position as of Q2 2018 after selling out during the quarter.
  • Lyon Street Capital sold 32,841 UroGen Pharma shares in Q2 2018, an estimated $1.63M.
  • Lyon Street Capital first reported a position in UroGen Pharma in Q3 2017 and held it in 3 quarters.
  • Lyon Street Capital's UroGen Pharma position peaked at $2.11M in Q4 2017.
  • 60 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2018.

Based on Lyon Street Capital's 13F filing for Q2 2018, filed 14 Aug 2018.